Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash from Investing Activities (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Cash from Investing Activities readings, the most recent being -$6.5 million for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities rose 68.15% to -$6.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$46.4 million, a 8191.43% decrease, with the full-year FY2025 number at -$46.4 million, down 8191.43% from a year prior.
  • Cash from Investing Activities hit -$6.5 million in Q4 2025 for Amicus Therapeutics, down from -$1.3 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $86.6 million in Q1 2021 to a low of -$68.1 million in Q4 2021.
  • Median Cash from Investing Activities over the past 5 years was $16.6 million (2021), compared with a mean of $11.1 million.
  • Biggest five-year swings in Cash from Investing Activities: surged 122.44% in 2021 and later crashed 536.0% in 2025.
  • Amicus Therapeutics' Cash from Investing Activities stood at -$68.1 million in 2021, then rose by 2.03% to -$66.7 million in 2022, then surged by 64.08% to -$24.0 million in 2023, then grew by 14.88% to -$20.4 million in 2024, then skyrocketed by 68.15% to -$6.5 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$6.5 million (Q4 2025), -$1.3 million (Q3 2025), and -$5.8 million (Q2 2025) per Business Quant data.